中国生物科技服务(08037)预计中期股东应占亏损同比减少约59%

Group 1 - The company expects a significant reduction in loss for the first half of 2025, with an estimated loss not exceeding 33 million HKD, compared to a loss of 79.917 million HKD in the same period of 2024, representing a decrease of approximately 59% [1] - The improvement in operational performance is primarily attributed to successful cost control measures, which have led to an increase in gross margin and a reduction in administrative expenses [1] - The company also received compensation income of approximately 14 million HKD from insurance claims related to damages caused by heavy rainfall to construction sites in Hainan during 2024 [1]